| P/E (FY) | 18.8 | Sales (TTM) | $3.17B |
| Earnings (TTM) | $1.29B | ROE | 19.71% |
| Net Margin | 41.94% | ROIC | 22.60% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | 22.92% | Sales Growth 3Y | 18.02% |
United Therapeutics develops and commercializes products for patients with chronic and life-threatening diseases in the United States and internationally. Its pulmonary arterial hypertension treatments include Tyvaso DPI and Nebulized Tyvaso, Remodulin injection, Orenitram tablets, and Adcirca. It also markets Unituxin, a monoclonal antibody for high-risk neuroblastoma, and the Remunity Pump system.
| Market Cap | $22.23B | Trading Days | 5292 |
| 52W High | 609.35 |
| 52W Low | 272.12 |
| % Off High | −14.07% |
| YTD | 7.47% | 1Y | 75.63% |
| 3Y | 113.58% | 5Y | 182.34% |
| 10Y | 340.06% | Since incept. (ann.) | 15.21% |
US 95% · Non Us 5%
| Ann. Volatility (1Y) | 47.76% | Ann. Volatility (3Y) | 37.00% |
| Sharpe (1Y) | 1.41 | Sharpe (3Y) | 0.88 |
| Max Drawdown (1Y) | −12.25% | Max Drawdown (3Y) | −33.00% |
| Beta (3Y, vs SPY) | 0.27 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| INSM | INSMED Inc | $22.57B | — |
| VTRS | Viatris Inc | $20.80B | — |
| ZLAB | Zai Lab Ltd | $20.39B | — |
| ROIV | Roivant Sciences Ltd. | $24.34B | — |
| BBIO | BridgeBio Pharma, Inc. | $16.76B | — |
| JAZZ | Jazz Pharmaceuticals plc | $16.12B | — |
| ZTS | Zoetis Inc. | $32.49B | 12.9 |
| RPRX | Royalty Pharma plc | $33.85B | 33.7 |
| QNRX | Quoin Pharmaceuticals, Ltd. | $14.09B | — |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $36.88B | 26.2 |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $38.25B | 123.8 |
| ELAN |
| Elanco Animal Health Inc |
| $12.75B |
| — |